Introduction: Oral biotin supplements taken by patients for various inherited metabolic diseases, demyelinating diseases, or to enhance hair and nail growth, can interfere with certain streptavidin-biotin-based immunoassays, as previously described for certain thyroid function tests. Such interference may cause false-positive (over-estimation) and false-negative (under-estimation) results in competitive and non-competitive immunoassays, respectively. Objective: We investigated the effect of biotin interference in two streptavidin-biotin-based, serologic assays, VITROS Hepatitis B e antigen (HBeAg) and VITROS Hepatitis B e antibodies (anti-Hbe; Ortho-Clinical Diagnostics). Methods: HBeAg and anti-HBe are noncompetitive and competitive immunoassays, respectively, and both were performed with the fully automated VITROS ECi Immunodiagnostic System (Ortho-Clinical Diagnostics). Aliquots of serum were prepared from pooled clinical specimens with three different signal/cutoff (S/CO) ratios, 0.21 (negative), 32.4 (reactive), and 2,220 (reactive) for HBeAg; and cutoff/signal (CO/S) ratios, 0.18 (negative), 2.59 (reactive), and 26.6 (reactive) for anti-HBe. These aliquots were spiked with a 0.9% NaCl solution containing 10,000 ng/mL biotin (Sigma-Aldrich) to achieve final biotin concentrations of 0, 10, 50, 100, 500, and 1,000 ng/mL, and were tested in duplicate for HBeAg and anti-HBe. A difference of >14% between observed and expected S/CO or CO/S ratios was considered significant change, based on manufacturer's precision data for these two assays. Results: HBeAg and anti-HBe immunoassays exhibited significant increases of observed S/CO and CO/S, respectively, ranging from 15% to 99% for HBeAg and from 17% to >1,000% for anti-HBe, at the biotin concentrations evaluated. Significant changes in qualitative interpretative results were observed in HBeAg-reactive and anti-HBe-negative serum samples.
Conclusion:
The VITROS HBeAg and anti-HBe immunoassays are susceptible to biotin interference, leading to a clinically significant change in qualitative interpretive results of originally borderline HBeAg-reactive and originally anti-HBe-negative specimens. Clinical laboratories should recognize that the patient's use of biotin-containing supplements might adversely affect certain laboratory test results.
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Diagnosis of Trichomoniasis in Men by Urine Cytology: Epidemiologic and Clinical Implications
Arslan Ahmad, MD, Derek Laskar, MD, Alejandro Zuretti, MD; 1 SUNY Downstate Health Science Center, Brooklyn, NY Background: Trichomoniasis is the most prevalent non-viral sexually transmitted infection worldwide. It is caused by the protozoan Trichomonas vaginalis, and the estimated global incidence is over 170 million cases per year, with over 8 million new cases per year in the United States alone. Up to 70% affected are asymptomatic; when symptoms do occur, dysuria, dyspareunia, urethritis, and vaginitis can be observed. Additionally, women are affected at higher rates than men. Despite the relative large overall annual incidence, very few reports have described the characteristics of male patients with T. vaginalis organisms on cytology. Method: We sought to determine the incidence and clinical significance of this finding in the urine cytology of male patients at our medium-sized academic medical center located in a major urban area. We retrospectively reviewed our archived urine cytology slides that reported T. vaginalis organisms spanning a 15-year period. Clinical histories from men with Trichomonas-positive urine were also reviewed and correlated. Slides were reviewed, and the morphologic characteristics of the organisms were recorded. Results: T. vaginalis were detected in nine of 5,094 urine cytology specimens (0.1%). The patients included six women and three men. The age range for men with Trichomonas-positive urine was from 29 to 52 years (mean age, 44 years; median age, 51 years). On cytologic review, T. vaginalis organisms were pear-shaped, oval, or round; they had cyanophilic staining with often evident eosinophilic cytoplasmic granules; there were pale nuclei; and eccentrically located flagella occasionally observed. Acute inflammation was observed in two of three cases. Clinical history was available in three of three men. Lower urinary tract symptoms were reported in three of three men, most commonly hematuria.
During organ procurement, each minute is critical. Turnaround time from receipt of the biopsy to read time may cause unnecessary delay in recovery. Occasionally, the recovering surgeon will delay organ recovery until the biopsy report has been issued. Due to the critical need for viable organs for transplantation, the Center for Organ Recovery and Education's (CORE) laboratory personnel have implemented steps to reduce turnaround time from receipt of biopsy until pathology review. CORE's laboratory is cross-trained to perform frozen section biopsy preparation for kidney and liver. Implementation of a cryo-embedder was the first step to reduce turnaround time. The Peltier element within the cryostat takes approximately 10 minutes to freeze sections. Using a face-down embedding technique, the cryo-embedder freezes the biopsy within 45-60 seconds, thereby reducing the process by up to nine minutes. The use of an automated stainer permits time for last-minute review and preparation of the reader. Implementation of digital pathology for remote evaluation permits the pathologists to evaluate and report, leading to overall time reduction. Additionally, improvements of processing technique by the CORE laboratory have impacted overall turnaround time. In the first quarter of 2016, average cutting time from receipt of sample until completion averaged 14 minutes. By the fourth quarter of 2016, average cutting time reduced to 10 minutes. Average total process time for the first quarter of 2016 was 23 minutes. Average total process time at the end of the fourth quarter of 2016 was 19 minutes, a reduction of 4 minutes, demonstrating reduction due to increased proficiency of personnel. The implementation of frozen section processing began in the second quarter of 2015, with turnaround times averaging 42.5 minutes. By end of the fourth quarter of 2016, the turnaround time averaged 25.5 minutes, resulting in a 40% overall reduction. Keeping track of this information can be particularly challenging when a laboratory offers many tests that require multiple reagents and components. Our previous Excel-based inventory listed all the reagents and supplies in alphabetical order. As new tests were added to the laboratory menu, and more reagents were added to the inventory list, it became apparent that the system was not efficient. The inventory was redesigned in an effort to make it easier to use and include more information. Methods: We designed an Excel file with worksheets for each test performed in the laboratory; each worksheet contained all reagents and components used to perform that test. Four new columns were added to record information on who received a shipment, which lot number was currently in use, which specimens were used for validation, and a space for comments. A "Review Worksheet" was generated in another tab to view all reagents and their history currently in use.
Efficient Inventory Control in the Laboratory
Conclusions:
The redesigned inventory is more organized and contains more information than the previous one. It can track the history of each reagent and its performance; there is a place to record defective lot numbers. All reagents and components for a particular test are in the same worksheet; if a reagent changes, it is quickly added to the list. The review worksheet is particularly effective; technologists quickly find out which lot numbers are being used and which ones need to be validated at the beginning of their monthly rotations, and the supervisor knows at a glance which reagents are being used in the laboratory at any time. 
